The novel nicotinic receptor antagonist N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens

Shafiqur Rahman, Nichole M. Neugebauer, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin, Michael T. Bardo*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

The current study examined the effect of the novel nicotinic acetylcholine receptor antagonist, N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), on nicotine-induced dopamine metabolism in rat nucleus accumbens, striatum and medial prefrontal cortex. Acute nicotine (0.5 mg/kg, s.c.) produced an increase in the content of dihydroxyphenylacetic acid (DOPAC) in nucleus accumbens, but not in striatum or medial prefrontal cortex. Pretreatment with bPiDDB (1 or 3 mg/kg, s.c.) dose-dependently inhibited the nicotine-induced increase in DOPAC content in nucleus accumbens. These results indicate that bPiDDB inhibits the nicotine-induced increase in DOPAC in reward-relevant brain region targeting nicotinic acetylcholine receptors.

Original languageEnglish (US)
Pages (from-to)103-105
Number of pages3
JournalEuropean Journal of Pharmacology
Volume601
Issue number1-3
DOIs
StatePublished - Dec 28 2008

Keywords

  • DOPAC
  • Dopamine metabolism
  • HPLC
  • Nicotinic receptor
  • Nucleus accumbens
  • bPiDDB

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'The novel nicotinic receptor antagonist N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens'. Together they form a unique fingerprint.

Cite this